Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Non-Hodgkin Lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results